Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan designation for treatment of leishmaniasis, according to a post on the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
- Novartis announces results from Phase III program for OAV101 IT
- Trump Trade: Administration explores simplified plans for reciprocal tariffs
- Big pharma fears drug price spikes in US-EU tariff spat, Reuters says
- Novartis shareholders approve dividend increase to CHF 3.50 per share
Questions or Comments about the article? Write to editor@tipranks.com